9 citations
,
January 2018 in “Acta Clinica Croatica” This review suggests that bendamustine, alone or in combination, shows effectiveness in treating indolent non-Hodgkin lymphoma and chronic lymphocytic leukemia, with recent studies highlighting its benefits especially in combination therapies, while balancing efficacy with a favorable toxicity profile.
24 citations
,
July 2013 in “Oncologist” This study suggests that the combination of bendamustine and rituximab is at least as effective and possibly offers a better therapeutic index than other standard regimens as first-line treatment for certain lymphoma patients.
September 2012 in “International Current Pharmaceutical Journal” In this study, CHOP chemotherapy for intermediate grade Non-Hodgkin's Lymphoma showed predictable toxicities but was generally well tolerated without treatment interruption among most patients.
February 2026 in “World Academy of Sciences Journal” This case report describes a rare occurrence of primary cutaneous diffuse large B-cell lymphoma, not otherwise specified (PCDLBCL-NOS) on the scalp of a 45-year-old female, highlighting its unusual presentation and the initial treatment response but also noting severe subsequent complications.
46 citations
,
December 1997 in “Cancer Nursing” In this study, patients receiving CHOP chemotherapy for aggressive non-Hodgkin's lymphoma reported a wide range of side effects, with all experiencing hair loss by cycle 3 and fatigue as a common issue.